However, this preliminary study has allowed re-designing a 12-color panel combining backbone markers from the EF AML/MDS panel with the myeloid lineage-associated markers, such as CD13, CD64, CD36, CD105, CD71, and CD33 that could improve the discriminatory potential between myHPCs and AML blasts. The gene discussed is CD36; the disease is acute myeloid leukemia.